Background The lack of systematic evidence on leptomeningeal enhancement (LME) on
MRI in neurological diseases, including multiple sclerosis (MS), hampers its interpretation in …

The brain is protected by the endothelial blood–brain barrier (BBB) that limits the access of
micro‐organisms, tumour cells, immune cells and autoantibodies to the parenchyma …

Advances in biomarker‐driven therapies for patients with nonsmall cell lung cancer
(NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for …

Simple Summary Leptomeningeal disease in melanoma (LMM) patients is characterized by
aggressiveness and dismal outcomes. Clinical studies and case reports demonstrate the …

Abstract Purpose of Review Headaches are a common, oftentimes debilitating symptom in
patients with leptomeningeal metastases. Recent Findings The third edition of the …

The leptomeninges, the cerebrospinal-fluid-filled tissues surrounding the central nervous
system, play host to various pathologies including infection, neuroinflammation and …

Leptomeningeal disease (LMD) remains a major challenge in the clinical management of
metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD …

Background Leptomeningeal disease (LMD) is a complication distinguished by progression
of metastatic disease into the leptomeninges and subsequent spread via cerebrospinal fluid …

Background It is a critical challenge to diagnose leptomeningeal metastasis (LM), given its
technical difficulty and the lack of typical symptoms. The existing gold standard of …

Leptomeningeal disease occurs when cancer cells migrate into the ventricles of the brain
and spinal cord and then colonize the meninges of the central nervous system. The triple …